GenoScreen announces the launch of Clear Dx™ Deeplex® Myc-TB, developed in collaboration with Clear Labs.
This next-generation solution fully automates the widely adopted Deeplex® Myc-TB assay, enabling rapid and comprehensive detection of drug resistance mutations and genotyping of Mycobacterium tuberculosis complex (MTBC), and broad identification of non-tuberculous mycobacteria (NTM). The product is available for Research Use Only (RUO).
Press release
GenoScreen and Clear Labs Announce the Launch of Clear Dx™ Deeplex® Myc-TB, an Automated Genomic Solution for Mycobacterium Characterization and TB Drug Resistance Detection
Lille, France – August 26, 2025 – GenoScreen, a biotechnology company pioneering advanced sequencing-based diagnostics, announces the launch of Clear Dx™ Deeplex® Myc-TB, developed in collaboration with Clear Labs. This next-generation solution fully automates the widely adopted Deeplex® Myc-TB assay, enabling rapid and comprehensive detection of drug resistance mutations and genotyping of Mycobacterium tuberculosis complex (MTBC), and broad identification of non-tuberculous mycobacteria (NTM). The product is now available for Research Use Only (RUO).
Tuberculosis (TB) remains a leading infectious killer worldwide, estimated to cause 10 million new cases and 1.5 million deaths each year by the World Health Organization. The rise of multidrug-resistant TB (MDR-TB) poses an urgent global health threat, while NTMs are emerging as increasingly significant pathogens linked to pulmonary and other forms of infections. These challenges highlight the critical need for accurate, rapid, and scalable molecular solutions.
Addressing Global Health Challenges with Precision Genomics
Conventional TB diagnostics including culture-based drug susceptibility testing are laborious and slow—often requiring weeks for results. Building on GenoScreen’s expertise in targeted next-generation sequencing (tNGS), the Deeplex® Myc-TB assay has already been recognized internationally as a game changer tool for rapid and extensive drug resistance profiling, directly from clinical specimens. By integrating Deeplex® Myc-TB onto the Clear Dx™ automated platform, GenoScreen and Clear Labs are making next-day genomic insights accessible with minimal hands-on time, reducing barriers for research and clinical laboratories worldwide.
Key features of Clear Dx™ Deeplex® Myc-TB include:
- Fully automated sequencing workflow: delivering sample-to-result insights with minimal manual intervention.
- Comprehensive identification: accurate detection of both MTBC and NTM species directly from clinical DNA.
- Faster turnaround: results available within 24 hours, compared to weeks with culture-based methods.
- Strain genotype and drug resistance mutation detection: robust genomic insights supporting surveillance of resistant TB strains.
- Scalable and compatible: designed for high-throughput research environments and integrated with Clear Dx™ workflows.
A strategic collaboration for a greater impact
"We are excited about our partnership with Clear Labs to commercialize the Clear Dx™ Deeplex® Myc-TB” said André Tordeux, CEO of GenoScreen. "This collaboration merges our advanced TB drug resistance detection technology with Clear Labs' automated platform, providing the healthcare and scientific community with a seamless, efficient solution for mycobacterial identification and profiling of drug resistance mutations. Together, we're advancing TB research and offering labs the tools they need to better understand and tackle this critical global health challenge."
"We are excited to bring Clear Dx™ Deeplex® Myc-TB to market, offering an efficient, automated solution built on an established, well-regarded assay, with the goal of accelerating the fight against TB," said Sasan Amini, CEO at Clear Labs. "This product not only enhances lab operations by improving efficiency and accuracy but also addresses key gaps in rapid Mycobacterium characterization. We're confident it will be a valuable tool for the clinical and scientific community."
About GenoScreen
GenoScreen is a biotechnology company based in Lille, France. The company develops NGS-based solutions for infectious disease research and diagnostics. With a particular focus on tuberculosis and antimicrobial resistance, the company's innovations include the Deeplex® range of products, which enables precise, rapid and extensive sequencing-based microbial characterisation. The company collaborates with leading public health institutions, clinical laboratories and research organisations around the world to address today's global health challenges.
About Clear Labs
Clear Labs is democratizing genomics with the fully automated, next-generation sequencing (NGS) platform for precision medicine and applied markets. Powered by its best-in-class technology that delivers unmatched accuracy and efficiency through sample-to-answer automation, Clear Labs' turnkey solutions are built to meet the complex and evolving needs of clinical, public health, and applied markets, by enabling them to perform advanced genomics in-house in their own labs. Clear Labs simplifies workflows to improve the speed, reliability, and cost of sequencing for faster decision-making, reduced operational costs, and ultimately, better health outcomes for all.
For more information on GenoScreen and Deeplex® Myc-TB, visit www.genoscreen.fr
Media:
GenoScreen, +33(0)62 263 777, This email address is being protected from spambots. You need JavaScript enabled to view it.
SOURCE GenoScreen